3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
10
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Breast Neoplasms
2
Salivary Gland Neoplasms
1
Prostate Cancer Non-Metastatic
1
Non-metastatic Prostate Cancer
1
Neoplasms
1
Healthy Volunteers
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Cancer Female
1
Biochemically Recurrent Prostate Cancer
1
Advanced Prostate Carcinoma
1
Interventions
enzalutamide
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Biochemically Recurrent Prostate Cancer
×
darolutamide
×
Clear all
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts